Swedish Orphan Biovitrum AB (FRA:B6E)

€ 24.42 -0.08 (-0.33%) Market Cap: 8.36 Bil Enterprise Value: 10.02 Bil PE Ratio: 42.61 PB Ratio: 2.56 GF Score: 88/100

Q1 2024 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Apr 25, 2024

€23.84 (+4.20%)

Earnings
Q4 2023 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Feb 08, 2024

€22.74 (-8.53%)

Earnings
Q3 2023 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Oct 30, 2023

€19.49 (+3.56%)

Earnings
Swedish Orphan Biovitrum AB (publ) KOL Haemophilia Call (Virtual) Transcript
Sep 18, 2023
Swedish Orphan Biovitrum AB (publ) KOL Event Call Transcript
Jul 19, 2023
Q2 2023 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Jul 18, 2023

€17.72 (+4.16%)

Earnings
Swedish Orphan Biovitrum AB (publ) to Acquire CTI Biopharma Corp Call Transcript
May 10, 2023
Q1 2023 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Apr 27, 2023

€21.27 (-2.88%)

Earnings
Q4 2022 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Feb 08, 2023

€20.51 (+3.77%)

Earnings
Q3 2022 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Oct 27, 2022

€17.64 (-2.59%)

Earnings
Q2 2022 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Jul 19, 2022

€20.57 (+5.95%)

Earnings
Q1 2022 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Apr 28, 2022

€19.11 (-4.26%)

Earnings
Q4 2021 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Feb 10, 2022

€16.9 (-2.83%)

Earnings
Q2 2021 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Jul 21, 2021

€15.45 (+4.52%)

Earnings
Q1 2021 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
May 04, 2021

€12.95 (-5.90%)

Earnings
Q4 2020 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Feb 18, 2021

€13.94 (-9.97%)

Earnings
Swedish Orphan Biovitrum AB (publ) Capital Markets Day Transcript
Dec 10, 2020
Q3 2020 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Oct 22, 2020

€14 (-4.53%)

Earnings
Q2 2020 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Jul 16, 2020

€17.97 (-10.79%)

Earnings
Q1 2020 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Apr 29, 2020

€16.1 (-4.67%)

Earnings
Q4 2019 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Feb 13, 2020

€16.22 (-1.68%)

Earnings
Q3 2019 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Oct 31, 2019

€13.46 (-6.81%)

Earnings
Swedish Orphan Biovitrum AB (publ) to Acquire Dova Pharmaceuticals Creating a Global Growth Platform in Haematology Call Transcript
Sep 30, 2019
Q2 2019 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Jul 17, 2019

€18.56 (+9.01%)

Earnings
Swedish Orphan Biovitrum AB (publ) Capital Markets Day Transcript
May 14, 2019
Q1 2019 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Apr 25, 2019

€16.24 (-10.41%)

Earnings
Q4 2018 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Feb 20, 2019

€17.67 (-5.37%)

Earnings

Q1 2021 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript

May 04, 2021 / 11:00AM GMT

Release Date Price: €12.95 (-5.90%)

Transcript

Operator

Ladies and gentlemen, welcome to the Sobi presentation for Q1 results.

(Operator Instructions)

I will now hand over to Guido Oelkers, CEO. Please go ahead.

Guido Oelkers;publ;CEO;President

Swedish Orphan Biovitrum AB

()-&

Yes. Thank you so much, and welcome to Sobi's Q1 conference. We are in an exciting period for the company. And before going into the presentation, a quick reminder of the forward-looking statement as per usual. I'm joined today by Henrik Stenqvist, CFO of the company; and Ravi Rao, the Head of R&D.

Q1 is a quarter that deserves a second look and I'll come back to this in a moment. However, first I want to draw your attention to what we have achieved during the first 3 months. Substantial growth in our launch business. Particular, with Doptelet, we more than tripled in Q1 versus last year. We had -- we stayed competitive in our Haemophilia business and showed significant patient growth versus Q1 last year. We had strong earnings in the quarter, and we delivered

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.